Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

457 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial.
Modjarrad K, Roberts CC, Mills KT, Castellano AR, Paolino K, Muthumani K, Reuschel EL, Robb ML, Racine T, Oh MD, Lamarre C, Zaidi FI, Boyer J, Kudchodkar SB, Jeong M, Darden JM, Park YK, Scott PT, Remigio C, Parikh AP, Wise MC, Patel A, Duperret EK, Kim KY, Choi H, White S, Bagarazzi M, May JM, Kane D, Lee H, Kobinger G, Michael NL, Weiner DB, Thomas SJ, Maslow JN. Modjarrad K, et al. Among authors: michael nl. Lancet Infect Dis. 2019 Sep;19(9):1013-1022. doi: 10.1016/S1473-3099(19)30266-X. Epub 2019 Jul 24. Lancet Infect Dis. 2019. PMID: 31351922 Free PMC article. Clinical Trial.
Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. rgp160 Phase II Vaccine Investigators.
Birx DL, Loomis-Price LD, Aronson N, Brundage J, Davis C, Deyton L, Garner R, Gordin F, Henry D, Holloway W, Kerkering T, Luskin-Hawk R, McNeil J, Michael N, Foster Pierce P, Poretz D, Ratto-Kim S, Renzullo P, Ruiz N, Sitz K, Smith G, Tacket C, Thompson M, Tramont E, Yangco B, Yarrish R, Redfield RR. Birx DL, et al. J Infect Dis. 2000 Mar;181(3):881-9. doi: 10.1086/315308. J Infect Dis. 2000. PMID: 10720508 Clinical Trial.
Selective increases in HIV-specific neutralizing antibody and partial reconstitution of cellular immune responses during prolonged, successful drug therapy of HIV infection.
Kim JH, Mascola JR, Ratto-Kim S, VanCott TC, Loomis-Price L, Cox JH, Michael NL, Jagodzinski L, Hawkes C, Mayers D, Gilliam BL, Birx DC, Robb ML. Kim JH, et al. Among authors: michael nl. AIDS Res Hum Retroviruses. 2001 Jul 20;17(11):1021-34. doi: 10.1089/088922201300343708. AIDS Res Hum Retroviruses. 2001. PMID: 11485619
The protective effect of circumcision on HIV incidence in rural low-risk men circumcised predominantly by traditional circumcisers in Kenya: two-year follow-up of the Kericho HIV Cohort Study.
Shaffer DN, Bautista CT, Sateren WB, Sawe FK, Kiplangat SC, Miruka AO, Renzullo PO, Scott PT, Robb ML, Michael NL, Birx DL. Shaffer DN, et al. Among authors: michael nl. J Acquir Immune Defic Syndr. 2007 Aug 1;45(4):371-9. doi: 10.1097/QAI.0b013e318095a3da. J Acquir Immune Defic Syndr. 2007. PMID: 17558336
Induction of HIV-specific functional immune responses by a multiclade HIV-1 DNA vaccine candidate in healthy Ugandans.
Eller MA, Eller LA, Opollo MS, Ouma BJ, Oballah PO, Galley L, Karnasuta C, Kim SR, Robb ML, Michael NL, Kibuuka H, Wabwire-Mangen F, Graham BS, Birx DL, de Souza MS, Cox JH. Eller MA, et al. Among authors: michael nl. Vaccine. 2007 Nov 7;25(45):7737-42. doi: 10.1016/j.vaccine.2007.08.056. Epub 2007 Sep 17. Vaccine. 2007. PMID: 17920731 Clinical Trial.
457 results